Novartis receives FDA approval for Cosentyx to treat adolescents with Hidradenitis Suppurativa

USA—The US Food and Drug Administration has approved Novartis’ Cosentyx (secukinumab) for treating pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

This approval establishes Cosentyx as the first interleukin-17A (IL-17A) inhibitor authorized for this age group, providing a new biologic treatment option for young patients struggling with this challenging condition.

Hidradenitis suppurativa is a chronic, systemic inflammatory skin disease characterized by recurring boil-like lesions that can rupture and transform into painful wounds.

The condition often leads to scarring and significantly impacts patients’ quality of life, particularly during the already challenging adolescent years.

Tailored treatment approach

The IL-17A mechanism of action in Cosentyx offers physicians a differentiated therapeutic approach for managing hidradenitis suppurativa in younger patients.

The medication’s dosing regimen is specifically tailored according to patient weight, ensuring appropriate treatment levels for adolescents and teenagers.

The approval for patients aged 12 years and older with a minimum weight of 30 kilograms draws support from multiple sources of clinical evidence.

Studies conducted in adult populations, combined with pharmacokinetic modeling extrapolated from clinical trials in adult hidradenitis suppurativa and psoriasis patients, formed the foundation of the regulatory submission.

Robust clinical evidence

The FDA further supported its approval decision through dosing analysis that predicted weight-based Cosentyx dosing would deliver similar drug exposure in pediatric and adult hidradenitis suppurativa patients.

Additional pediatric data from other approved uses of Cosentyx contributed to the comprehensive evidence package presented to regulators.

Victor Bultó, Novartis US President, emphasized the significance of this approval for young patients who have faced limited treatment options.

He highlighted that Cosentyx brings more than a decade of real-world experience across multiple autoimmune diseases, making it a well-established treatment option that many physicians trust.

Addressing unmet medical needs

Bultó noted that young people living with moderate to severe hidradenitis suppurativa have contended with limited treatment choices for far too long.

The expansion of Cosentyx to this population addresses a critical gap in care and demonstrates Novartis’ focus on advancing solutions where the company can make the greatest impact on patient outcomes.

The executive stressed that providing effective treatment options during adolescence can prevent long-term complications and improve the overall disease trajectory for young patients with this debilitating skin condition.

Broad therapeutic applications

Cosentyx currently holds FDA approval for treating adults with several conditions, including ankylosing spondylitis, hidradenitis suppurativa, non-radiographic axial spondyloarthritis, plaque psoriasis, and psoriatic arthritis.

The medication also has pediatric indications for hidradenitis suppurativa, enthesitis-related arthritis, juvenile psoriatic arthritis, and plaque psoriasis.

This diverse range of approved indications reflects the versatility of IL-17A inhibition as a therapeutic mechanism across various inflammatory conditions affecting different patient populations.

In a separate development last month, Novartis signed a research partnership and licensing agreement with Unnatural Products valued at up to USD 1.7 billion.

The collaboration focuses on developing macrocyclic peptide therapeutics targeting cardiovascular diseases, expanding Novartis’ pipeline beyond inflammatory conditions into the cardiovascular space.

This partnership demonstrates the pharmaceutical company’s continued commitment to innovation and strategic investments in emerging therapeutic modalities